Integration of Molecular Profiling into the Lung Cancer Clinic
Authors:
- William PaoWPWilliam Pao
- Mark G. KrisMKMark G. Kris
- A. John IafrateAIA. John Iafrate
- Marc LadanyiMLMarc Ladanyi
- Pasi A. JännePJPasi A. Jänne
- Ignacio I. WistubaIWIgnacio I. Wistuba
- Ryn Miake-LyeRMRyn Miake-Lye
- Roy S. HerbstRHRoy S. Herbst
- David P. CarboneDCDavid P. Carbone
- Bruce E. JohnsonBJBruce E. Johnson
- Thomas J. LynchTLThomas J. Lynch
- 31 August 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (17) , 5317-5322
Abstract
Individuals from five thoracic oncology centers in the United States recently met to discuss how to integrate molecular profiling into the care of all patients with carcinoma of the lung. Lung cancer is an area of medical oncology in which clinicians are beginning to use specific tumor-associated molecular aberrations to assign and/or prioritize targeted therapies for patients. At this early stage, multiple hurdles remain before molecular profiling becomes a routine part of thoracic oncology practice. Concrete collaborative next steps were discussed that could help lead to standardized methods across institutions. In particular, to develop specific targeted therapies for patients whose tumors harbor rare mutations, it will be important for multiple institutions to work together to identify appropriate candidates, design the appropriate trials, and execute the trials with adequate numbers to achieve the necessary end points. Implementation will facilitate realization of the promise of molecularly tailored therapy, which could lead to more effective treatments with fewer side effects. (Clin Cancer Res 2009;15(17):5317–22)Keywords
This publication has 16 references indexed in Scilit:
- Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment ResponseClinical Cancer Research, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersLung Cancer, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLOS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004